Archive for September, 2009
Micell Technologies receives $15 million from St. Jude Medical, GlaxoSmithKline curbs its funding educational programs that bring doctors up-to-date, Duke Genome Center gets a $19.5 million grant and a consortium of area universities and nonprofit organizations are chasing a piece of the $63 billion the Obama Administration wants to spend over the next six years on global health care programs.
Remember cold fusion? Most scientists believe the dream of generating an abundance of cheap energy by fusing two atomic nuclei at room temperature is dead after a 1989 tabletop experiment couldn’t be repeated and its results were questioned.
When a Washington think tank went looking for ideas to influence how the U.S. might spend $63 billion in the next six years improving the health of people in poor countries, it came to North Carolina’s Research Triangle Park.
Salix Pharmaceuticals, a Morrisville company that specializes in gastrointestinal treatments, has seen its shares rise nearly 50 percent in the past two days.
Investors rushed to trade the stock after Salix announced results from two late-stage studies Monday that showed rifaximin works better than placebo in treating non-constipation irritable bowel syndrome. Salix sells rifaximin for traveler’s diarrhea under the name Xifaxan.
GlaxoSmithKline gets good news on its Cervarix vaccine and bad news on its blockbuster asthma treatment Advair, the N.C. Biotechnology Center prepares to build a $10.4 million expansion with the help of private donations and Quintiles Transnational gets ready for Clinical Research Education Day at N.C. Central University.